CCM
VIR icon

Coldstream Capital Management’s Vir Biotechnology VIR Stock Holding History

Coldstream Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-89
Closed -$577 – 3287
2025
Q1 		$577 Buy
+89
New +$791 ﹤0.01% 3317

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coldstream Capital Management's VIR Position: Q2 2025 in Review

Coldstream Capital Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 89 shares — an estimated $577 sold.

Coldstream Capital Management first reported a position in VIR in Q1 2025 and held it in 1 quarter. The position peaked at $577 in Q1 2025. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Coldstream Capital Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 89 Vir Biotechnology shares in Q2 2025, an estimated $577.
  • Coldstream Capital Management first reported a position in Vir Biotechnology in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Vir Biotechnology position peaked at $577 in Q1 2025.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.